Abstract
Not only the many number of the patients, the biology, treatment pattern and clinical outcomes are different in Asian gastric cancer patients compared to Western area. Recently the communications and collaborations between Asia/East and West are increasing in gastric cancer research and drug development including global clinical trials. Even though many molecular targeted agents (MTA) are developed and trastuzumab is introduced in treatment of Her-2 positive gastric cancer, there are no specific and effective MTAs for gastric cancer, yet.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
